AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-commitment + gain frame messages
Number of subjects: 196486
Study 34472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss frame messages alone
Number of subjects: 196486
Study 34472020 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain frame messages alone
Number of subjects: 196486
Study 34472020 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 196486
Study 35442367 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 66
Study 35442367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 66
Study 33625939 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of promethazine
Number of subjects: 0
Study 33625939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34730795 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150/300 mg
Number of subjects: 204
Study 34730795 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study 32475155 — intervention group
Group type: EXPERIMENTAL
Intervention: Whiteboard video for HCPs and trainees outlining strategies to communicate about weight
Number of subjects: 70
Study 34570042 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week home-based walking program
Number of subjects: 0
Study 34570042 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 0
Study 32188502 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (24 IU intranasal)
Number of subjects: 45
Study 32188502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 36410690 — intervention group
Group type: EXPERIMENTAL
Intervention: BaP‐Enjoying Family Life
Number of subjects: 72
Study 36410690 — intervention group
Group type: COMPARATOR
Intervention: EPEC‐Being a Parent
Number of subjects: 72
Study 34710590 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention comprising team-based didactic instruction with live observation at a TRA-proficient lab, followed by a visit from a cardiologist and catheterization laboratory nurse coaching team.
Number of subjects: 0
Study 34710590 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32708938 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) training
Number of subjects: 40
Study 32708938 — intervention group
Group type: COMPARATOR
Intervention: Standard Rehabilitation (SR)
Number of subjects: 40
Study 34994232 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 + alcohol
Number of subjects: 20
Study 34994232 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP8062 alone
Number of subjects: 20
Study 34994232 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 20
Study 34994232 — intervention group
Group type: COMPARATOR
Intervention: Placebo + alcohol
Number of subjects: 20
Study 34994232 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 20
Study 33141935 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediate provisionalization (Group A: n = 20)
Number of subjects: 40
Study 33141935 — intervention group
Group type: COMPARATOR
Intervention: Immediate implant placement with delayed provisionalization (Group B: n = 20)
Number of subjects: 40
Study 33141935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study 33770684 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg finerenone
Number of subjects: 0
Study 33770684 — intervention group
Group type: COMPARATOR
Intervention: Capillary plasma sampling
Number of subjects: 0
Study 32607644 — intervention group
Group type: EXPERIMENTAL
Intervention: LCIG infusion plus three oral doses of placebo
Number of subjects: 13
Study 32607644 — intervention group
Group type: EXPERIMENTAL
Intervention: LCIG
Number of subjects: 13
Study 32607644 — intervention group
Group type: COMPARATOR
Intervention: Oral immediate-release carbidopa/levodopa (LC-IR)
Number of subjects: 13
Study 32607644 — intervention group
Group type: COMPARATOR
Intervention: LC-IR
Number of subjects: 13
Study 33278599 — intervention group
Group type: COMPARATOR
Intervention: S-1 (40-60 mg twice daily for 4 weeks on/2 weeks off for 1 year)
Number of subjects: 546
Study 33278599 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) (130 mg/m2 every 3 weeks for 6 months)
Number of subjects: 546
Study 33278599 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX plus chemoradiotherapy (SOXRT) (45 Gy)
Number of subjects: 546
Study 34601044 — intervention group
Group type: EXPERIMENTAL
Intervention: eAVG
Number of subjects: 477
Study 34601044 — intervention group
Group type: COMPARATOR
Intervention: sAVG
Number of subjects: 477
Study 33000465 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab 300 mg every 2 weeks (Q2W)
Number of subjects: 0
Study 33000465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33402624 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal excavation and LSTR with triple antibiotic paste (TAP)
Number of subjects: 42
Study 33402624 — intervention group
Group type: COMPARATOR
Intervention: Traditional indirect pulp treatment with calcium hydroxide
Number of subjects: 42
Study 34455578 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone I (0 to 40 mm from the root apex)
Number of subjects: 6
Study 34455578 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone II (40 to 80 mm from the root apex)
Number of subjects: 6
Study 34455578 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA expression
Number of subjects: 6
Study 34455578 — intervention group
Group type: EXPERIMENTAL
Intervention: Target genes of differentially expressed miRNAs in root zone II
Number of subjects: 6
Study 34455578 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of ptc-miR169d target NFYA3
Number of subjects: 6
Study 34406235 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled long wavelength ray light regimen
Number of subjects: 0
Study 34406235 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (uncontrolled light regimen)
Number of subjects: 0
Study 36084082 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden for 10 days
Number of subjects: 312
Study 36084082 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 312
Study 33002377 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg heat therapy (HT) 3 times/week for 6 weeks using water-circulating trousers at 48°C
Number of subjects: 32
Study 33002377 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg heat therapy (HT)
Number of subjects: 32
Study 33002377 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 32
Study 35125434 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART mHealth app intervention
Number of subjects: 34
Study 34051211 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroShunt
Number of subjects: 527
Study 34051211 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 527
Study 32892987 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Antiplatelet Therapy (SAPT)
Number of subjects: 610
Study 32892987 — intervention group
Group type: COMPARATOR
Intervention: Dual Antiplatelet Therapy (DAPT)
Number of subjects: 610
Study 34337012 — intervention group
Group type: EXPERIMENTAL
Intervention: MMED+AFS+BMSCs
Number of subjects: 45
Study 34337012 — intervention group
Group type: EXPERIMENTAL
Intervention: MMED+AFS
Number of subjects: 45
Study 34337012 — intervention group
Group type: EXPERIMENTAL
Intervention: MMED
Number of subjects: 45
Study 35854331 — intervention group
Group type: EXPERIMENTAL
Intervention: Coparenting-focused intervention (eight classes: four during and four following pregnancy)
Number of subjects: 110
Study 35854331 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 110
Study 34142951 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic metformin hydrochloride (850 mg)
Number of subjects: 36
Study 34142951 — intervention group
Group type: COMPARATOR
Intervention: Glucophage (reference preparation)
Number of subjects: 36
Study 32076783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) treatment
Number of subjects: 1767
Study 32076783 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1767
Study 32519394 — intervention group
Group type: EXPERIMENTAL
Intervention: Clipped sites
Number of subjects: 13
Study 32519394 — intervention group
Group type: COMPARATOR
Intervention: Unclipped sites
Number of subjects: 13
Study 32564889 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy followed by preoperative chemotherapy and surgery
Number of subjects: 0
Study 32564889 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36353406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL)
Number of subjects: 43
Study 36353406 — intervention group
Group type: COMPARATOR
Intervention: Procedural sedation (PS)
Number of subjects: 43
Study 32464334 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-valent HPV vaccine (6/11/16/18)
Number of subjects: 3817
Study 32464334 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3817
Study 36431312 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation and intensive one-to-one training (NEURO®)
Number of subjects: 0
Study 36431312 — intervention group
Group type: COMPARATOR
Intervention: Conventional NEURO® occupational therapy
Number of subjects: 0
Study 32053984 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut group (1, 1.5, or 2 oz. of walnuts daily)
Number of subjects: 698
Study 32053984 — intervention group
Group type: COMPARATOR
Intervention: Control group (habitual diet, no walnuts or tree nuts)
Number of subjects: 698
Study 32053984 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut group
Number of subjects: 698
Study 32053984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 698
Study 36178527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hug robotic transfer support device
Number of subjects: 0
Study 35438586 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Behavior Therapy for Children with Selective Mutism (IBTSM)
Number of subjects: 30
Study 33152122 — intervention group
Group type: EXPERIMENTAL
Intervention: levosimendan
Number of subjects: 2385
Study 33152122 — intervention group
Group type: COMPARATOR
Intervention: epinephrine
Number of subjects: 2385
Study 33152122 — intervention group
Group type: COMPARATOR
Intervention: dopexamine
Number of subjects: 2385
Study 33152122 — intervention group
Group type: COMPARATOR
Intervention: enoximone
Number of subjects: 2385
Study 33152122 — intervention group
Group type: COMPARATOR
Intervention: dopamine-milrinone
Number of subjects: 2385
Study 35114491 — intervention group
Group type: EXPERIMENTAL
Intervention: BEMER® blanket
Number of subjects: 12
Study 35114491 — intervention group
Group type: COMPARATOR
Intervention: Placebo blanket
Number of subjects: 12
Study 35114491 — intervention group
Group type: COMPARATOR
Intervention: No blanket
Number of subjects: 12
Study 34153979 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 27
Study 34153979 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 27
Study 32451241 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTitouch adaptive compression therapy (ACT) system
Number of subjects: 56
Study 32451241 — intervention group
Group type: COMPARATOR
Intervention: Multilayered bandage (MLB) compression systems
Number of subjects: 56
Study 36041341 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fidelity model
Number of subjects: 62
Study 36041341 — intervention group
Group type: COMPARATOR
Intervention: High-fidelity model (cadaver)
Number of subjects: 62
Study 34491021 — intervention group
Group type: EXPERIMENTAL
Intervention: Kynurenic acid 0.5% (FS2) cream (Group 1)
Number of subjects: 0
Study 34491021 — intervention group
Group type: COMPARATOR
Intervention: Active onion extract comparator treatment (Group 2)
Number of subjects: 0
Study 34491021 — intervention group
Group type: COMPARATOR
Intervention: Inactive vehicle (Group 3)
Number of subjects: 0
Study 32026257 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at 0 ng·ml‐1
Number of subjects: 40
Study 32026257 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil at 1 ng·ml‐1
Number of subjects: 40
Study 32026257 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 3 ng·ml‐1
Number of subjects: 40
Study 32026257 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at 5 ng·ml‐1
Number of subjects: 40
Study 35818033 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote data collection (caregiver weight, child height and weight)
Number of subjects: 38
Study 35531914 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) to 33°C
Number of subjects: 0
Study 35531914 — intervention group
Group type: COMPARATOR
Intervention: Targeted normothermia (37.5°C)
Number of subjects: 0
Study 32050055 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl (10 mg)
Number of subjects: 20
Study 32050055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene HCl (10 mg)
Number of subjects: 20
Study 32050055 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study 35947827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin 34 mg
Number of subjects: 18
Study 35947827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 35947827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin (in subgroup analysis)
Number of subjects: 18
Study 33773103 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine plus naloxone therapy
Number of subjects: 0
Study 33773103 — intervention group
Group type: COMPARATOR
Intervention: Referral for methadone maintenance therapy
Number of subjects: 0
Study 33227793 — intervention group
Group type: EXPERIMENTAL
Intervention: CAABMR group
Number of subjects: 365
Study 33227793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 365
Study 34951474 — intervention group
Group type: EXPERIMENTAL
Intervention: Warrior Programme intervention (Time Line Therapy™)
Number of subjects: 52
Study 34951474 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 32961529 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon band with ipsilateral ulnar artery compression (group 2)
Number of subjects: 253
Study 32961529 — intervention group
Group type: COMPARATOR
Intervention: Single-bladder radial compression band (group 1)
Number of subjects: 253
Study 36109438 — intervention group
Group type: EXPERIMENTAL
Intervention: Office bleaching
Number of subjects: 180
Study 36109438 — intervention group
Group type: EXPERIMENTAL
Intervention: Home bleaching
Number of subjects: 180
Study 36109438 — intervention group
Group type: COMPARATOR
Intervention: Control group for office bleaching
Number of subjects: 180
Study 36109438 — intervention group
Group type: COMPARATOR
Intervention: Control group for home bleaching
Number of subjects: 180
Study 32888826 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5mg inhaled lancovutide (once daily, every other day or twice a week) for eight weeks
Number of subjects: 161
Study 32888826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 161
Study 32506233 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressor test
Number of subjects: 0
Study 32506233 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 33472052 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation-based AF rhythm control with optimal HF therapy and aggressive catheter ablation (PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug)
Number of subjects: 600
Study 33472052 — intervention group
Group type: COMPARATOR
Intervention: Rate control with optimal HF therapy and measures to achieve resting HR < 80 bpm and 6-minute walk HR < 110 bpm
Number of subjects: 600
Study 33275775 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg elemental selenium daily)
Number of subjects: 90
Study 33275775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 33275775 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 90
Study 33023544 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet need for contraception
Number of subjects: 386
Study 33023544 — intervention group
Group type: COMPARATOR
Intervention: Age 20-24 years
Number of subjects: 386
Study 33023544 — intervention group
Group type: COMPARATOR
Intervention: Age 30 years and above
Number of subjects: 386
Study 33023544 — intervention group
Group type: COMPARATOR
Intervention: Uneducated women
Number of subjects: 386
Study 33023544 — intervention group
Group type: COMPARATOR
Intervention: Unaware of family planning
Number of subjects: 386
Study 33023544 — intervention group
Group type: COMPARATOR
Intervention: Not previously practiced contraception
Number of subjects: 386
Study 35377385 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding educational intervention along with standard care
Number of subjects: 80
Study 35377385 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 33781372 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV study group
Number of subjects: 134
Study 33781372 — intervention group
Group type: COMPARATOR
Intervention: Tabata high‐intensity control group
Number of subjects: 134
Study 33781372 — intervention group
Group type: COMPARATOR
Intervention: Vinyasa yoga low‐intensity control group
Number of subjects: 134
Study 35029187 — intervention group
Group type: EXPERIMENTAL
Intervention: antihypertensive drugs + acupuncture
Number of subjects: 158
Study 35029187 — intervention group
Group type: COMPARATOR
Intervention: antihypertensive drugs + sham acupuncture
Number of subjects: 158
Study 34440352 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric muscle work (CMW)
Number of subjects: 80
Study 34440352 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric muscle work (EMW)
Number of subjects: 80
Study 34440352 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric‐eccentric muscle work (C‐EMW)
Number of subjects: 80
Study 34440352 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscular work (IMW)
Number of subjects: 80
Study 34440352 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE DD genotype
Number of subjects: 80
Study 34440352 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTN3 RR genotype
Number of subjects: 80
Study 36207870 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors
Number of subjects: 140
Study 33773580 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (40 mg.kg−1 bolus and 20 mg.kg−1.h−1 infusion)
Number of subjects: 64
Study 33773580 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (3 mg.kg−1 bolus and 3 mg.kg−1.h−1 infusion)
Number of subjects: 64
Study 33773580 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium plus lidocaine (equal doses of both drugs)
Number of subjects: 64
Study 33773580 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic solution)
Number of subjects: 64
Study 32238166 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT) for 30 minutes
Number of subjects: 0
Study 32238166 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise (CONT) for 30 minutes
Number of subjects: 0
Study 35005038 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages (56 messages between 13 and 40 gestational weeks)
Number of subjects: 66
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on age-friendly domains
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on neighborhood parks and streets
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on transportation
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on sidewalks
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on social and educational activities
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on community participation
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on loneliness
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on community connection
Number of subjects: 656
Study 33291242 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on Internet access
Number of subjects: 656
Study 32564649 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARe program (weekly eight-session, 12-hour group program)
Number of subjects: 62
Study 32564649 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 62
Study 33169490 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided Internet-based cognitive-behavioral therapy (iCBT)
Number of subjects: 128
Study 33169490 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 128
Study 36460266 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT-ARFID)
Number of subjects: 100
Study 36460266 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational Motivation Therapy (PMT)
Number of subjects: 100
Study 32533883 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 250
Study 32533883 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (Cu-IUD)
Number of subjects: 250
Study 32533883 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal implantable contraceptives
Number of subjects: 250
Study 34758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily)
Number of subjects: 5661
Study 34758252 — intervention group
Group type: COMPARATOR
Intervention: Ramipril (5 mg twice daily)
Number of subjects: 5661
Study 34758252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Number of subjects: 5661